Dilated Cardiomyopathy – Pipeline Review, H1 2020 | Key Players Include Berlin Cures Holding AG, Celixir, Heartseed Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dilated Cardiomyopathy – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

It provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Dilated Cardiomyopathy – Overview
• Dilated Cardiomyopathy – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Dilated Cardiomyopathy – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Dilated Cardiomyopathy – Companies Involved in Therapeutics Development
• Berlin Cures Holding AG
• Celixir Ltd
• Heartseed Inc
• Martin Pharmaceuticals Inc
• MyoKardia Inc
• Olagenesis Corp
• Pfizer Inc
• Renovacor Inc
• Shionogi & Co Ltd
• Dilated Cardiomyopathy – Drug Profiles
• BC-007 – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy – Drug Profile
• Heartcel – Drug Profile
• HS-001 – Drug Profile
• PF-06802861 – Drug Profile
• redasemtide – Drug Profile
• SAR-440181 – Drug Profile
• Small Molecules for Dilated Cardiomyopathy – Drug Profile
• Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy – Drug Profile
• trimetazidine – Drug Profile
• YS-1402 – Drug Profile
• Dilated Cardiomyopathy – Dormant Projects
• Dilated Cardiomyopathy – Product Development Milestones
• Featured News & Press Releases
• Appendix
  

Companies Mentioned

• Berlin Cures Holding AG
• Celixir Ltd
• Heartseed Inc
• Martin Pharmaceuticals Inc
• MyoKardia Inc
• Olagenesis Corp
• Pfizer Inc
• Renovacor Inc
• Shionogi & Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pmm2ph

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900